GSK considers licensing Cann’s CBD capsule
Premium
11 April 2022
GlaxoSmithKline (GSK) Consumer Healthcare is considering a licensing deal for Cann Group’s cannabidiol (CBD) capsule in Australia and other markets worldwide.